- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03869281
Fracture Risk After Pancreas Transplantation (FraPaT) (FRAPAT)
Effect of Type 1 Diabetes Remission by Pancreas Transplantation Alone on Fracture Risk: a Retrospective Matched Cohort Study
Individuals with type 1 diabetes (T1D) are at greater risk of fracture than non-diabetic subjects. Although the mechanisms underlying bone fragility in T1D are not completely understood, insulin deficiency seems to play a key role.
To date, no information is available on the effect of diabetes remission after pancreatic transplantation alone (PTA) on the risk of fractures in T1D individuals with preserved kidney function.
The overall objective of this retrospective cohort study is to evaluate the effect of T1D remission after PTA on fracture risk.
The primary endpoint will be the difference in fracture incidence (any fracture) between the PTA group and the control group. For the PTA group, the incidence of fractures after transplantation will be considered.
Data from patients who underwent PTA at IRCCS San Raffaele Hospital from January 2, 2005 to December 31, 2017 will be compared with age-, gender- and disease duration-matched controls from the pool of outpatients with T1D attending the Endocrinology Unit at the same Institution. Anthropometric, anamnestic, laboratory data and data on the history of fractures and past/current therapies will be collected.
With this study, for the first time we will be able to obtain information on the effects of diabetes remission on the risk of fracture. We expect that the remission of diabetes will result in a beneficial effect on the fracture risk.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Please Select
-
Milan, Please Select, Italy, 20123
- San Raffaele Scientific Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria (PTA group)
- T1D patients who received their first PTA, or second PTA only if their first graft was explanted within a week, between 2 January 2005 and 31 December 2017
- age ≥18 and < 65 years
- willingness to participate in this observational study
Inclusion Criteria (control group)
- Type 1 diabetes
- age ≥18 years and < 65 years
- willingness to participate in this observational study
- minimum disease duration of 5 years
- brittle diabetes, as defined by the occurrence of frequent acute complications (ketoacidosis or severe hypoglycaemic episodes requiring third-part assistance or unawareness despite well-conducted intensive insulin therapy)
- presence of at least one diabetes-related complication (either neuropathy, retinopathy, subclinical nephropathy).
Exclusion Criteria (both groups)
- conditions other than T1D known to affect bone health (i.e., non-compensated hypothyroidism, hyperthyroidism, hyperparathyroidism, inflammatory bowel disease, malignancy, rheumatoid arthritis, hypogonadism, severe chronic obstructive pulmonary disease, hepatic insufficiency, alcohol intake ≥ 3 units/day ),
- use of drugs that can affect bone metabolism (e.g., bisphosphonates, anticonvulsants, hormone replacement therapy) other than glucocorticoids and immunosuppressants
- recipients of simultaneous pancreas kidney transplantation, pancreatic islet transplantation, multiple PTAs, other transplants
- BMI <18.5 or ≥ 30 kg/m2
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
PTA
patients who underwent their first deceased donor PTA, or second deceased donor PTA if their first graft was explanted within a week, at the IRCCS San Raffaele Hospital between 2 January 2005 and 31 December 2017
|
Pancreas transplantation
|
Controls
outpatients with T1D attending the Endocrinology Unit at IRCCS San Raffaele Hospital and patients listed for a first deceased donor PTA
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fracture incidence
Time Frame: 02 January 2005 - 30 September 2018
|
Difference in fracture incidence (any fracture) between the PTA and the control group
|
02 January 2005 - 30 September 2018
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FRAPAT
- 155/INT/2018 (Other Identifier: Ethics Committee)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fractures, Bone
-
Lawson Health Research InstituteCompleted
-
AO Innovation Translation CenterRecruitingLong Bone FracturesUnited States, Canada, Australia, Ghana, Chile, China, Germany, India, Pakistan, Venezuela, Spain, Croatia, Greece
-
University Hospital, Clermont-FerrandRecruiting
-
Centre Hospitalier Universitaire Saint PierreRecruiting
-
McMaster UniversityMcMaster Surgical AssociatesCompleted
-
University of UtahCompletedBone Strength | Stress Fractures | Bone Geometry | Biomechanical ChangesUnited States
-
IlluminOss Medical, Inc.CompletedHumerus Fracture Metastatic Bone DiseaseUnited States
-
University of British ColumbiaCompleted
-
Novo Nordisk A/SCompletedBone Fracture | Tibia FracturesIsrael, Germany, Finland, Hungary, Spain, South Africa, Norway, France, Poland
-
Carlos A Acosta-OlivoCompletedRadius Fractures | Bone Fractures | Closed Fractures
Clinical Trials on Pancreas transplantation alone
-
Hospices Civils de LyonCompletedKidney Transplantation | Pancreas-kidney TransplantationFrance
-
University Health Network, TorontoEnrolling by invitationDiabetes Mellitus, Type 2 | OverweightCanada
-
University of OxfordRecruiting
-
Second Affiliated Hospital of Guangzhou Medical...Recruiting
-
Oslo University HospitalCompletedDiabetes Type 1 | Endothelial DysfunctionNorway
-
Andrew PosseltActive, not recruitingDiabetes Mellitus, Type 1United States
-
Patricia Sanchez VelazquezRecruiting
-
Oregon Health and Science UniversityProvidence Health & ServicesCompletedPancreas Cyst | Pancreas MassUnited States
-
Massachusetts General HospitalBoston UniversityCompletedType 1 DiabetesUnited States